Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2010

View Archived Issues

Amplyx Pharmaceuticals claims new HIV protease inhibitors

RARB, SLITS and WIF1 gene methylation status may predict cervical cancer

SPIRAL data show noninferiority of ritonavir- vs. raltegravir-based therapy in HIV-1 infection

Gardasil HPV vaccine is safe and efficacious in HM and MSM

PET imaging agent AV-133 distinguishes Alzheimer's disease from DLB

Inflammatory cytokines identified as putative biomarkers for AD

MabVax begins phase II trial of trivalent ganglioside vaccine in sarcoma

EMA recommends restricting modafinil use

VM Discovery discloses new Trk-A inhibitors

New GlyT-1 inhibitors discovered at Vanderbilt University

New sialidase inhibitors described at Simon Fraser University

NovaBay's NVC-422 is safe and efficacious against impetigo in phase II trial

Sumitomo Chemical presents new mPGES-1 inhibitors

Akebia begins phase IIa trial of AKB-6548 for anemia in patients with CKD

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

Almirall and Pfizer join to commercialize Conbriza for osteoporosis in Spain

MedImmune begins shipping FluMist influenza vaccine in U.S.

NovImmune and Genentech collaborate on IL-17-directed antibody

CHMP issues positive opinion on Twynsta for hypertension

Abraxane approved in Japan for breast cancer

FDA approves Oxford BioMedica's phase II trial of MVA-5T4 in prostate cancer

FDA approves Aricept 23-mg tablet for Alzheimer's disease

Enrollment begins in phase III trial of BHR-100 for traumatic brain injury

Sanofi-aventis expresses reservations regarding FDA approval of new version of enoxaparin sodium

Cerenis Therapeutics raises funds to develop HDL therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...